PHAXIAM Therapeutics Past Earnings Performance
Past criteria checks 0/6
PHAXIAM Therapeutics has been growing earnings at an average annual rate of 20.2%, while the Biotechs industry saw earnings growing at 15.8% annually. Revenues have been growing at an average rate of 3.1% per year.
Key information
20.2%
Earnings growth rate
30.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 3.1% |
| Return on equity | -32.6% |
| Net Margin | -209.8% |
| Next Earnings Update | 20 Mar 2024 |
Recent past performance updates
Recent updates
ERYTECH receives non-compliance letter from Nasdaq
Oct 13Erytech Pharma reports 1H results
Sep 12Erytech drops plans to pursue FDA approval for leukemia therapy
Aug 24Our First Look At ERYTECH Pharma
Nov 16ERYTECH Pharma S.A. 2021 Q1 - Results - Earnings Call Presentation
May 06ERYTECH starts patient enrollment in pancreatic cancer study
Jan 14ERYTECH secures €10M in non-dilutive financing
Nov 02ERYTECH: Trials In Pancreatic Cancer
Oct 23Revenue & Expenses BreakdownBeta
How PHAXIAM Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 6 | -12 | 15 | 6 |
| 30 Jun 23 | 6 | -11 | 12 | 10 |
| 31 Mar 23 | 6 | 6 | 12 | 14 |
| 31 Dec 22 | 7 | 0 | 14 | 20 |
| 30 Sep 22 | 2 | -18 | 14 | 31 |
| 30 Jun 22 | 3 | -27 | 15 | 35 |
| 31 Mar 22 | 3 | -54 | 16 | 43 |
| 31 Dec 21 | 4 | -54 | 16 | 45 |
| 30 Sep 21 | 4 | -61 | 16 | 49 |
| 30 Jun 21 | 4 | -66 | 15 | 52 |
| 31 Mar 21 | 4 | -68 | 15 | 53 |
| 31 Dec 20 | 4 | -73 | 15 | 58 |
| 30 Sep 20 | 4 | -73 | 15 | 58 |
| 30 Jun 20 | 4 | -68 | 15 | 58 |
| 31 Mar 20 | 5 | -69 | 17 | 58 |
| 31 Dec 19 | 5 | -63 | 17 | 52 |
| 30 Sep 19 | 6 | -52 | 18 | 45 |
| 30 Jun 19 | 5 | -49 | 18 | 39 |
| 31 Mar 19 | 4 | -38 | 17 | 35 |
| 31 Dec 18 | 4 | -38 | 15 | 33 |
| 30 Sep 18 | 3 | -42 | 13 | 33 |
| 30 Jun 18 | 4 | -38 | 12 | 30 |
| 31 Mar 18 | 3 | -39 | 10 | 27 |
| 31 Dec 17 | 3 | -34 | 9 | 25 |
| 30 Sep 17 | 4 | -27 | 7 | 23 |
| 30 Jun 17 | 4 | -26 | 6 | 23 |
| 31 Mar 17 | 5 | -24 | 7 | 22 |
| 31 Dec 16 | 4 | -22 | 7 | 20 |
| 30 Sep 16 | 4 | -20 | 8 | 17 |
| 30 Jun 16 | 4 | -19 | 9 | 14 |
| 31 Mar 16 | 3 | -16 | 8 | 12 |
| 31 Dec 15 | 3 | -15 | 8 | 11 |
| 30 Sep 15 | 3 | -14 | 7 | 10 |
| 30 Jun 15 | 2 | -12 | 5 | 10 |
| 31 Mar 15 | 2 | -11 | 5 | 8 |
| 31 Dec 14 | 2 | -9 | 4 | 7 |
| 30 Sep 14 | 2 | -8 | 4 | 6 |
| 30 Jun 14 | 2 | -7 | 4 | 5 |
| 31 Mar 14 | 2 | -8 | 4 | 5 |
| 31 Dec 13 | 2 | -8 | 4 | 5 |
| 30 Sep 13 | 4 | -5 | 3 | 4 |
| 30 Jun 13 | 6 | -2 | 3 | 4 |
| 31 Mar 13 | 6 | -2 | 3 | 3 |
Quality Earnings: PHXM is currently unprofitable.
Growing Profit Margin: PHXM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PHXM is unprofitable, but has reduced losses over the past 5 years at a rate of 20.2% per year.
Accelerating Growth: Unable to compare PHXM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PHXM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: PHXM has a negative Return on Equity (-32.64%), as it is currently unprofitable.